Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6847761 | 0.97 | TDP1 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Acetic Acid SCHEMBL1588800 | 0.95 | TDP1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Acetic Acid SCHEMBL4482555 | 0.95 | TDP1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Acetic Acid SCHEMBL5762920 | 0.95 | TDP1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Bicarbonate SCHEMBL9490608 | 0.91 | HDAC1 (0.52) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Bicarbonate SCHEMBL14245001 | 0.91 | HDAC1 (0.52) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Acetone SCHEMBL290188 | 0.91 | TDP1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Bicarbonate SCHEMBL7424110 | 0.91 | HDAC1 (0.52) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Bicarbonate SCHEMBL28420339 | 0.88 | CHRM1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Acetic Acid SCHEMBL1244963 | 0.88 | CHRM1 (0.41) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111492497-B | Charge-transporting varnish and charge-transporting film | 日产化学株式会社 | 2023-05-26 | — | — | CN | disclosed |
| CN-105358556-B | New compound for selective histone deacetylase inhibitor and the pharmaceutical composition comprising it | 株式会社钟根堂 | 2018-01-02 | — | — | CN | disclosed |
| EP-2903609-B1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| CN-106146484-A | Quinazoline derivant is as RAF kinase modulator and their method and purposes | 埃姆比特生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-105658646-A | Aminoheteroaryl benzamides as kinase inhibitors | 诺华股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| CN-102666531-A | Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2012-09-12 | — | — | CN | disclosed |
| CN-102438990-A | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2012-05-02 | — | — | CN | disclosed |
| CN-100384892-C | Catalysts for olefin polymerization | DU PONT (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-100369940-C | Olefin polymerization catalyst | DU PONT (US) | 2008-02-20 | — | — | CN | disclosed |
| CN-1277824-C | Piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| CN-1802350-A | Azetidinecarboxamide derivatives and their use in the treatment of CB1Use in receptor-mediated disorders | VERNALIS RES LTD (GB) | 2006-07-12 | — | — | CN | disclosed |
| CN-1626558-A | Catalysts for olefin polymerization | DU PONT (US) | 2005-06-15 | — | — | CN | disclosed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | disclosed |
| US-20040101864-A1 | Chemical process | ATRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| CN-1444606-A | Olefin polymerization catalyst | DU PONT (US) | 2003-09-24 | — | — | CN | disclosed |
| US-5696155-A | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | BOEHRINGER MANNHEIM BMBH (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5446065-A | Thromboxane antagonists | BOEHRINGER MANNHEIM GMBH (DE) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101864-A1 | Chemical process | ASS1, SRM, SRMS | TDP1 1623/4885CHRM1 2507/4885AKR1A1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.